Study to evaluate Acute Myeloid Leukemia in teenagers

Patients are needed to participate in a clinical research study of FT-1101 to evaluate Acute Myeloid Leukemia, Acute Myelogenous Leukemia or Myelodysplastic Syndrome (MDS).

Purpose: This is an open-label, multicenter, dose-escalation Phase 1 study in patients with acute leukemia or high-risk MDS, intended to investigate safety, pharmacokinetics, and the pharmacodynamic effects of FT-1101 administered via one or more intermittent dosing schedules. Once the MTD has been established, up to 42 additional patients may be enrolled in 3 expansion cohorts in selected patient populations at the recommended dose for future studies to confirm safety.
Gender:
Both Male and Female.
Age:
18 and up.